Oral platelet inhibitors proving difficult

Despite the success of injectable platelet inhibitors such as Centocor Inc.'s ReoPro abciximab, Cor Therapeutics Inc.'s Integrilin eptifibatide and Merck & Co. Inc.'s Aggrastat tirofiban, oral versions of the GPIIb/IIIa antagonist class have been hard to come by. Nevertheless, the potential market for an oral platelet inhibitor is so enticing that development efforts are expected to continue despite several setbacks.

F. Hoffmann-La